Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dhruv Vyas

Internal Medicine Eden, NC Medical Doctor

NPI 1437257706 CMS profile 247224

405 Thompson St, Eden, NC 27288

Open in the dashboard

General payments

$3,591

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dhruv Vyas of Eden, NC is reported in the CMS Open Payments database as having received $3,591 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $229 12
2024 General $398 22
2023 General $202 11
2022 General $17 1
2021 General $84 6
2020 General $999 79
2019 General $1,662 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dhruv Vyas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dhruv Vyas were reported at $229. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dhruv Vyas Internal Medicine median Middle half National median
2019 $1,662 $159 $48–$570 $163
2020 $999 $119 $33–$402 $114
2021 $84 $135 $37–$521 $132
2022 $17 $141 $42–$496 $149
2023 $202 $149 $45–$519 $160
2024 $398 $154 $47–$537 $164
2025 $229 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $698 28 payments
  2. Novo Nordisk Inc $398 52 payments
  3. GlaxoSmithKline, LLC. $340 22 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $270 18 payments
  5. Pfizer Inc. $194 14 payments
  6. Novartis Pharmaceuticals Corporation $184 13 payments
  7. Lilly USA, LLC $140 11 payments
  8. Amgen Inc. $138 11 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $118 9 payments
  10. Sanofi-Aventis U.S. LLC $116 8 payments
  11. Other $994 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,591 252 payments
Products named General payments · program years 2019–2025
  1. SYMBICORT $342 6 payments
  2. FARXIGA $312 4 payments
  3. Ozempic $284 36 payments
  4. BEVESPI AEROSPHERE $276 7 payments
  5. TRELEGY ELLIPTA $219 13 payments
  6. BRILINTA $218 3 payments
  7. RYBELSUS $204 27 payments
  8. BYDUREON $195 1 payment
  9. ENTRESTO $184 13 payments
  10. Tresiba $168 28 payments
  11. Other $3,629 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 223 drugs

Part D claims

25,872

Median for Internal Medicine: 777

Drug cost

$1,425,711

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 215 $163,710
Eliquis Apixaban Brand 224 $158,186
Jardiance Empagliflozin Brand 178 $133,586
Ozempic Semaglutide Brand 103 $111,404
Mounjaro Tirzepatide Brand 84 $88,145
Xarelto Rivaroxaban Brand 124 $70,144
Tresiba Flextouch U-200 Insulin Degludec Brand 86 $60,275
Farxiga Dapagliflozin Propanediol Brand 57 $50,458
Tresiba Flextouch U-100 Insulin Degludec Brand 61 $48,017
Januvia Sitagliptin Phosphate Brand 51 $42,261

The 10 drugs with the highest cost, of 223 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$284,902

Of which drugs: $9,932

Medicare patients

488

Average age 76

Services billed

10,016

308 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 37%
Chronic kidney disease 28%
Depression 23%
Ischemic heart disease 22%
COPD 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 74 74 $6,055
Injection, methylprednisolone acetate, 80 mg J1040 Office 25 30 $138
Injection, methylprednisolone acetate, 40 mg J1030 Office 21 25 $71
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 76 $38
Injection, methylprednisolone acetate, 1 mg J1010 Office 72 266 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $26
$26 — —
SYNJARDY
  • Boehringer Ingelheim Pharmaceuticals, Inc. $20
$20 — —
NURTEC ODT
  • PFIZER INC. $19
$19 — —
NUEDEXTA
  • Otsuka America Pharmaceutical, Inc. $18
$18 — —
RYBELSUS
  • Novo Nordisk Inc $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record